(Vp/F) of ceftibuten-cis ranged from 0.21 to 0.24 liter/kg in subjects in group I, I, m, and IV. V/F was significantly greater in the group V subjects with end-stage renal disease (V/F, 0.39 + 0.27 liters/kg). These changes in Vp/F cannot be separated from possible changes in bioavailability. The maximum concentration of ceftibuten-trans in plasma was significantly higher and occurred significantly later in group IV subjects than it did in subjects in the other groups. The terminal elimination half-life of ceftibuten-trans was significantly and progressively prolonged as CLCR declined (2.63 ± 1.02, 5.37 ± 1.93, 14.29 ± 10.84, and 19.46 ± 9.69 h in groups I, II, III, and IV, respectively). The hemodialysis clearance of ceftibuten-cis was 76.9 ± 18.0 ml/min, and the fraction of the administered dose of ceftibuten-cis removed during -3 h of hemodialysis-was 39 ±%. Ceftibuten dosage adjustments are proposed for subjects with renal insufficiency.
Ceftibuten {(6R,7R)-7[(2)-2-(2-aminothiazol-4-yl)-4 carboxy-2-butenyolamino]-8-oxo-5-thia-1-azabicyclo [4, 2, 0] oct-2-ene-2 carboxylic acid; molecular weight, 410.43} ( Fig. 1 ) is an investigational, orally active broad-spectrum cephalosporin that has demonstrated in vitro antibacterial activity against a wide range of gram-negative and gram-positive bacteria (6) . In vitro studies have shown that 92% of all members of the family Enterobacteriaceae are susceptible to ceftibuten, whereas 78.7 and 45.1% are susceptible to cefixime and cefuroxime, respectively (7) . The activity of ceftibuten against 95 respiratory tract pathogens was superior or comparable to that reported for other oral cephalosporins such as cefprozil (BMY-28100), cefuroxime axetil, cefetamet (RO 15-8074), cefteram (RO 19-5247), and cefixime (7) .
Ceftibuten is administered as the active cis isomer and is excreted primarily in the urine. Approximately 70% of ceftibuten-cis is excreted unchanged in the urine of healthy volunteers, and the terminal elimination half-life (t12|2) is 2 to 3 h (1). Plasma protein binding of ceftibuten-cis approximates 65% in healthy subjects and is independent of the ceftibuten-cis concentration in plasma (12) . During multiple dosing of 200 mg of ceftibuten-cis twice daily in normal male volunteers, 94% of the drug was excreted in the urine ( eThree subjects were anuric; therefore, n = 3 for CLCRf Versus groups I, II, III, and IV, P < 0.05.
MATERIALS AND METHODS
Subjects and study design. Thirty subjects between the ages of 25 and 74 years participated in this study. The subjects were divided into five groups on the basis of their 24-h ambulatory creatinine clearance (CLCR). Subjects in group I had normal renal function (CLCR, >80 ml/min). Those in groups II, III, and IV were nondialyzed subjects with mild (CLCR, 50 to 80 mlmin), moderate (CLCR, 30 to 49 ml/min), or severe (CLCR, 5 to 29 ml/min) renal insufficiency, respectively. Subjects in group V were maintained on chronic hemodialysis three times weekly for a minimum of 12 weeks prior to entry into the study. The study was approved by the Hennepin County Medical Center's institutional review board. All subjects granted written informed consent before initiation of the study and underwent a complete physical examination, including electrocardiogram, a 24-h ambulatory CLCR, urinalysis, complete blood count with differential, and a multichannel chemistry profile before and after study completion.
None of the subjects had a history of or current evidence of hepatic disease, cardiovascular disorders, respiratory disease, gastrointestinal disorders, blood dyscrasias, rapidly changing renal function as addressed by historical data, or cancer. None of the subjects had received a renal transplant, nor had they received an investigational drug during the 4 weeks prior to thie study. Concurrent drug therapy included standard therapy for diseases related to renal insufficiency, such as hypertension, diabetes, and hyperparathyroidism.
Subjects were not on concomitant drug therapy known to affect the metabolic capacity or renal handling of drugs. These medications were continued unchanged for at least 14 days prior to the study and during the course of the investigation.
Subjects All blood samples were drawn into heparinized Vacutainer tubes. Plasma was harvested within 15 min of each sample collection. The plasma was pipetted into appropriately labeled polypropylene tubes, frozen, and maintained at -70°C until analysis.
The total urine outputs of subjects in groups I to IV were collected during the following time intervals: before (-12 to 0 h) and 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 48, 48 to 72, 72 to 96, and 96 to 120 h after drug administration. Urine volumes were quantified, and an aliquot was saved at -70°C until analysis.
During the hemodialysis phase for group V subjects, blood samples were obtained immediately before and at 0.5, 1, 2, and 3 h after drug administration. Paired arterial (predialysis filter) and venous (postdialysis filter) blood samples were obtained prior to and 0.5, 1, 2, and 3 h after the start of hemodialysis. Additional blood samples were obtained immediately at the cessation of hemodialysis and at 0.16, 0.33, 0.5, 0.75, 1, 2, 12, 24, 36, and 48 h after the end of hemodialysis.
For those subjects in group V who were not anuric, urine was collected during the following time intervals after each drug administration: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, and 24 to 48 h. Urine volumes were quantified, and an aliquot sample was saved at -70°C until analysis.
During the hemodialysis procedure, quantitated dialysate collections were performed over the following intervals after the initiation of hemodialysis: 0 to 0.5, 0.5 to 1, 1 to 2, and 2 to 3 h and 3 h to the end of hemodialysis. The total volume was measured, and an aliquot was frozen at -70°C until analysis.
Analytic procedures. The plasma, urine, and dialysate samples were analyzed for ceftibuten-cis and ceftibutentrans by a high-performance liquid chromatography method at Schering-Plough Corporation (1). The high-performance liquid chromatography method involves the addition of an internal standard (acyclovir) and 100 .1l of 0.2 M sodium phosphate buffer (pH 7) to a 100-,ul sample. A 5-p, sample of the resulting solution was then injected into a high-performance liquid chromatograph consisting of a ,uBondapak C18 column and a Waters model 440 absorbance detector with a fixed wavelength of 254 mm. The mobile phase consisted of acetonitrile and 0.05 M ammonium acetate (2:98; vol/vol) delivered at a flow rate of 1 ml/min. The assay was linear over a concentration range of 0.1 to 50 pug/ml. The highperformance liquid chromatography technique was precise and accurate down to 0.1 ,ug of ceftibuten-cis and ceftibutentrans per ml in plasma and dialysate and 0.5 ,ug/ml in urine. The intra-and interassay coefficients of variation were less than 5% in plasma, urine, and dialysate at concentrations of 5, 10, and 20 ,g/ml (12) .
Data analysis. The maximum ceftibuten-cis and ceftibuten- where A.el-t2 is the amount of ceftibuten-cis or ceftibutentrans recovered in the urine within a specific time interval (t1-t2), and AUCtl-t2 is the AUC during the same interval. The apparent nonrenal clearance of ceftibuten-cis (CLNR/F) was calculated as the difference between CLpIF and CLR.
The hemodialysis clearance (CLHD) of ceftibuten-cis, the clearance of blood urea nitrogen (BUN), and CLCR were calculated by the equation CLHD = AR/AUCHD, where AR is the total amount of ceftibuten-cis recovered in the dialysate, and AUCHD is the area under the arterial (predialysis filter) plasma concentration-time curve during hemodialysis. The apparent elimination rate constant of ceftibuten-cis during hemodialysis (kHD) was estimated by nonlinear regression analysis of all arterial (predialysis filter) plasma concentrations obtained during hemodialysis.
In vivo interconversion of ceftibuten-cis and ceftibutentrans was not accounted for in the data analysis.
Statistical analysis. Differences in pharmacokinetic parameters between the five groups were evaluated by one-way analysis of variance and the Duncan procedure post hoc test for significance (SPSS/PC + V2.0; SPSS, Inc.). The relationships between CLCR and CLp/F, CLCR and CLR, CLCR and I, CLCR and CLNR/F, and CLCR and V3/F were assessed by orthogonal regression analysis (9, 11) . The relationship between CLCR and CLp/F was used to project the dosage modifications of ceftibuten-cis for subjects with renal insufficiency.
Statistical significance was assessed at the P < 0.05 level. Data are expressed as mean ± standard deviation (SD). 
RESULTS
The five groups were not significantly different in sex distribution or height (Table 1) . However, subjects in group V weighed significantly less than subjects in groups I, II, and III. Thus, the dose of ceftibuten, in milligrams per kilogram of body weight, was larger in group V subjects (P < 0.05). In addition, subjects in group II were significantly older than subjects in group I. The single-dose ceftibuten-cis administration was well tolerated in all subjects.
The mean ceftibuten-cis plasma concentration-time curves are presented in Fig. 2 . The Cmax of ceftibuten-cis was significantly higher in group IV subjects than it was group I and III subjects ( Table 2 ). In addition, Cmax in group V subjects was higher than that in group I subjects. When Cmax was adjusted for body weight, group IV and V subjects had significantly larger Cmax values compared with those in group I, II, and III subjects. The mean Tmax of ceftibuten-cis was significantly longer in group IV subjects compared with that in subjects in all other groups ( + 2.7 ml/min for subjects in groups I, II, III, IV, and V, respectively. The CLR of ceftibuten-cis also progressively declined as renal function declined (Table 2) . Furthermore, the CLNR/F of ceftibuten-cis significantly declined as a function of renal insufficiency. The VpIF of ceftibuten-cis was not significantly different between subjects in groups I, II, III, and IV. However, Va3/F was significantly greater in group V subjects than it was in group I, II, and IV subjects; 0.39 ± 0.27 versus 0.21 ± 0.03, 0.22 ± 0.05, and 0.22 ± 0.5 liter/kg, respectively. The tl/2,3 of ceftibuten-cis was significantly prolonged in group V subjects compared with that in group I, II, III, and IV subjects. Additionally, the t1/2, of ceftibuten-cis for subjects in group IV was significantly prolonged compared with that in subjects in groups I, II, and III.
The ceftibuten-cis CLp/F [CLp/F = (0.569-CLCR) + 9.57; r2 = 0.855] (Fig. 3) Characteristics of the hemodialysis procedures and ceftibuten-cis pharmacokinetic parameters during and after hemodialysis are outlined in Table 3 . The time for a dialysis procedure was 179.3 ± 37.4 min. The dialyzer clearance of ceftibuten-cis was 76.9 + 18.0 ml/min, and the percentage of the administered dose of ceftibuten-cis recovered in the dialysate during hemodialysis was 39 + 9%. The CLHD of ceftibuten-cis was 25.6% of the CLHD of BUN and 34.8% of the CLHD of creatinine. The average elimination rate constant of ceftibuten-cis for all subjects during hemodialysis was 0.378 + 0.114 h-1, and the corresponding tl/2,3 of ceftibuten-cis during hemodialysis was 1.97 + 0.56 h. A rise in the ceftibuten-cis concentration in plasma was observed in all hemodialysis subjects within 10 min after the cessation of hemodialysis. The maximum increase in the concentration of ceftibuten-cis in plasma occurred at 0.58 + 0.31 h after the cessation of hemodialysis and represented an increase of 45.9 + 41.5% above the concentration in plasma measured at the cessation of hemodialysis. Thereafter, the ceftibuten-cis concentrations in plasma declined monoexponentially (Fig. 4) . The tl,2g of ceftibuten-cis after the redistribution period was 22.5 + 13.1 h and was not significantly different from the tl/2, observed after the interdialytic dose of ceftibuten-cis. Interfering substances were detected in the plasma, urine, and dialysate with the ceftibuten-trans analytical procedure in two subjects in group IV and all subjects in group V. This interference was not present in any biologic specimens from the other subjects for which data are reported.
The Cmax values of ceftibuten-trans in plasma ranged from 1.18 to 2.68 mg/liter at 1.75 to 11 .33 h following ceftibutencis administration (Fig. 5 and Table 4 ). The Cmax of ceftibuten-trans was significantly higher when it was normalized for body weight in group IV subjects in comparison with that in group II and III subjects, and the Tmax was significantly prolonged in group IV subjects in comparison with that in group I, II, and III subjects. The AUCo. of ceftibuten-trans significantly increased as CLCR declined. The t1/2, of ceftibuten-trans was significantly shorter in group I and II subjects than it was in group III and IV subjects. The t4/2, of ceftibuten-trans was not significantly different than the tl/2, of ceftibuten-cis in any of the groups. Although the CLR of ceftibuten-trans was approximately 10 times lower in group IV subjects compared with that in group I subjects, the difference did not achieve statistical significance. One subject from group I and one subject from group II had extremely high CLR values of ceftibuten-trans (group I subject, CLR = 170 ml/min; group II subject, CLR = 141 ml/min). If these data are excluded from the analysis, the CLR of ceftibuten-trans remains not significantly changed as CLCR declines (25.8 ± 13.9, 23.5 + 12.0, 15.1 + 7.6, and 6.5 + 7.2 ml/min in group I, II, III, and IV subjects, respectively). e There were only four subjects because of assay interference in the other two subjects.
DISCUSSION
The pharmacokinetics of ceftibuten in subjects with renal insufficiency are markedly altered from those observed in subjects with normal renal function. This was expected since approximately 70% of ceftibuten-cis is recovered unchanged in urine in subjects with normal renal function. Ceftibutencis CLp/F and CLNR/F strongly correlated with CLCR. The fact that the age of the subjects ranged from 27 to 70 years should not influence the data from this study, since age alone has no effect on ceftibuten disposition (1) .
The significant increase in the Cmax of ceftibuten-cis in the subjects with severe renal insufficiency may be due to a combination of increased F and/or decreased ,B of the drug. Renal insufficiency has been shown to reduce the F of some drugs, while it increases the F of others (2, 5) . When the ceftibuten-cis Cmax was adjusted for body weight (i.e., milligrams per liter per kilogram), the resulting mean Cmax was larger in group IV subjects than it was in group I subjects. There was also a delay in the absorption of ceftibuten-cis in subjects with severe renal insufficiency (group IV). However, this small change in ceftibuten-cis Cmax and Tm,. may not be clinically significant.
The Cmax, Tmax, AUCO, and t1/2, values of ceftibutentrans were significantly larger in the subjects with severe renal impairment not undergoing hemodialysis. Although the ratio of ceftibuten-trans to ceftibuten-cis AUCOO was not significantly different between subjects in the four groups, the P value was 0.078. Given these changes and the fact that ceftibuten-cis f decreased as a function of CLCR, it can be suggested that more drug may be metabolized to ceftibutentrans in these severely impaired subjects. There was not a statistically significant difference Iin the CLR of ceftibutentrans; however, this may have been due to insufficient statistical power. The t,/2,3 of ceftibuten-trans was not different from the tl/2,3 of ceftibuten-cis, therefore suggesting that the P of ceftibuten-trans is formation rate limited. The percentage of the administered dose of ceftibuten recovered in urine as ceftibuten-cis plus ceftibuten-trans was significantly greater in group I and II subjects than it was in subjects in groups III and IV (77.6 + 13.5, 67.8 ± 10.7, 55.7 + 17.5, and 46.5 + 15.3%, respectively).
Several methods for modification of the antibiotic dosage recommendation in subjects with reduced renal function have been suggested (4, 13) . To achieve the same average concentration in plasma in subjects with impaired renal function as that in normal subjects, the dose can be kept constant and the dosing interval can be changed. Alternatively, the dosing interval can be kept constant and the dose can be altered. Both of these methods give similar average steady-state concentrations, but they yield vastly different effects on the maximum and minimum drug concentrations.
Ceftibuten, as with most other cephalosporins, has not been associated with any concentration-dependent toxicity. Consequently, ceftibuten dose adjustments may not be necessary from a toxicity standpoint. However, dosage adjustments could yield a significant cost savings by reducing the amount of drug required to achieve and maintain therapeutic concentrations. The MIC for 90% of mo'st ceftibutensusceptible organisms ranges between 0.025 to 0.4 mg/liter. However, clinical response has been demonstrated with once-daily administration of ceftibuten, in which the concentrations in plasma may not exceed the MIC for the entire dosing interval (3). In randomized, single-blind trials, ceftibuten administered once daily at doses of 400 mg (or 6 mg/kg in children) demonstrated a response rate of 92 and 94% against streptococcal pharyngitis and otis media infections, respectively (8) . In patients with bronchitis treated with 400 mg of ceftibuten once daily, the infecting pathogens were eliminated from 85% of cases and the clinical response rate was 91% (8) . Similar response data for the treatment of urinary tract infections, pneumonia, and sinusitis infections with ceftibuten given at 400 mg once daily also have been defined (12) . On the basis of a dose of 400 mg of ceftibuten given orally every 24 h, the dose of ceftibuten should not need alteration until the CLCR drops below 49 ml/min. Table TABLE 5 a Ceftibuten was given to subjects in groups I to IV once every 24 h; hemodialysis patients received ceftibuten at 300 mg three times weekly, after hemodialysis.
CLCR, assuming a 90% F (1) and utilizing the average pharmacokinetic parameters for the CLCR group.
Ceftibuten is a low-molecular-weight compound that is soluble in water and has a relatively low extent of protein binding (although that was not assessed in the subjects in this study); therefore, as anticipated, much of it was removed by hemodialysis. The fraction of the ceftibuten dose removed during the 3-h hemodialysis procedure was 39%, and the CLHD of ceftibuten-cis was 25.6 and 34.8% of the simultaneous CLHD of BUN and creatinine, respectively. Therefore, in order to maintain effective concentrations of ceftibuten in plasma, a 300-mg dose of ceftibuten given three times weekly after hemodialysis should achieve effective concentrations in plasma (Cmax of 20 mg/liter and a trough concentration after hemodialysis of 1.5 mg/liter). These proposed dosage regimens need to be validated for their efficacy in infected patients.
